

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**November 3, 2010**  
**MINUTES**

**1. Call to Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 3, 2010.

**2. Welcome**

Debbie Tapley, RPh, called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Gregory Browning, MD  
Jody Bollinger, MD  
Debbie Tapley, RPh

Bruce Johnson, MD  
Kelly Jones, PharmD

Thomas Phillips, RPh  
Tan Platt, MD

**SC DHHS:**

Emma Forkner, Director  
Felicity Myers, PhD  
James Assey, RPh  
Deidra Singleton, JD  
Vicki Johnson, JD  
Valeria Williams

**Magellan Medicaid Administration:**

Bryan Amick, PharmD  
Mary Roberts, RPh

**Pharmaceutical Industry Speakers**

**4. Discussion Topics**

**A. Committee Meeting Minutes, Wednesday, August 4, 2010.**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

**B. SC DHHS Presentation**

Director Emma Forkner offered comments regarding the current budgetary concerns regarding the Medicaid program. The Medicaid population continues to grow, and is expected to total 865,000 by the end of the current fiscal year. With the 2014 eligibility changes mandated by the Affordable Care Act, the Medicaid population will grow to 1.2 to 1.4 million beneficiaries.

**C. Public Comment**

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

<b>COMPANY</b>	<b>SPEAKER</b>	<b>DRUG</b>
<i>No Public Comment Offered</i>		

**D. Drug Classes for Review**

Bryan Amick led the discussion for the following drug classes:

- Benzoyl Peroxide Products
- Benzoyl Peroxide/Clindamycin Combination Products
- Long Acting Insulins
- Short Acting Narcotic Analgesics

The following are the recommendations of the P & T Committee:

<b>BENZOYL PEROXIDE PREPARATIONS</b>	
Recommendation that generic benzoyl peroxide preparations will be preferred and brand products will require PA.	
<b>BENZOYL PEROXIDE/CLINDAMYACIN COMBINATIONS</b>	
<u>Preferred</u> BENZACLIN CLINDAMYCIN-BENZOYL PEROXIDE	<u>Non-Preferred</u> ACANYA GEL DUAC CS
<b>LONG ACTING INSULINS</b>	
<u>Preferred</u> LANTUS (Vial and Pen) LEVEMIR (Vial and Pen)	<u>Non-Preferred</u>

<b>SHORT ACTING NARCOTIC ANALGESICS</b>
Recommendation that generic short acting narcotics and combination products will be preferred and brand products will require PA.

5. **Old Business**

None

6. **New Business**

**Posting of Atypical Antipsychotics:** Director Forkner informed the Committee that the agency was looking to post all atypical antipsychotics as preferred to garner rebate dollars associated with their inclusion on the PDL. The Committee expressed approval of this approach

**Rosiglitazone:** The Committee voted to remove rosiglitazone from the preferred drug list and to require prior authorization for new patients started on any rosiglitazone containing products.

**OTC Utilization:** Dr. Jones requested that an evaluation of OTC products reimbursed by Medicaid be conducted.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS:

- Benzoyl Peroxide Products
- Benzoyl Peroxide/Clindamycin Combination Products
- Long Acting Insulins
- Short Acting Narcotic Analgesics

8. **Closing Comments**

The next meeting will be held on Wednesday, February 2, 2011, at 4:00 PM at the same location.

9. **Adjournment**

The meeting adjourned at 5:24 PM.